Combating immunosuppression in glioma.
Combating immunosuppression in glioma.
复制标题
DOI：
10.2217/14796694.4.3.433
复制
发表时间：
2008-06
期刊：
影响因子：
3.3
通讯作者：
E. A. Vega;M. Graner;J. Sampson
中科院分区：
文献类型：
--
作者：
E. A. Vega;M. Graner;J. Sampson
尽管最大限度的治疗，恶性胶质瘤有一个非常差的预后。神经胶质瘤患者表现出明显的免疫缺陷，包括CD 4淋巴细胞减少，外周血中调节性T细胞比例增加，细胞因子谱从Th 1向Th 2转变。最近的研究集中在神经胶质瘤患者以及神经胶质瘤动物模型中对抗免疫抑制的方法。我们集中在两个具体的方式来对抗免疫抑制：抑制TGF-β信号和调节T细胞的调制。TGF-β信号传导可通过反义寡核苷酸技术、TGF-β受体I激酶抑制剂、可溶性TGF-β受体和抗TGF-β的抗体中断。调节性T细胞已被针对T细胞标志物（如CD 25、CTLA-4和GITR）的抗体靶向。此外，还探索了针对Foxp 3的疫苗接种。这些研究的结果是令人鼓舞的;对抗免疫抑制可能是改善恶性胶质瘤预后的关键之一。
Despite maximal therapy, malignant gliomas have a very poor prognosis. Patients with glioma express significant immune defects, including CD4 lymphopenia, increased fractions of regulatory T cells in peripheral blood and shifts in cytokine profiles from Th1 to Th2. Recent studies have focused on ways to combat immunosuppression in patients with glioma as well as in animal models for glioma. We concentrate on two specific ways to combat immunosuppression: inhibition of TGF-beta signaling and modulation of regulatory T cells. TGF-beta signaling can be interrupted by antisense oligonucleotide technology, TGF-beta receptor I kinase inhibitors, soluble TGF-beta receptors and antibodies against TGF-beta. Regulatory T cells have been targeted with antibodies against T-cell markers, such as CD25, CTLA-4 and GITR. In addition, vaccination against Foxp3 has been explored. The results of these studies have been encouraging; combating immunosuppression may be one key to improving prognosis in malignant glioma.